Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23119130 | 1.00 | MME (0.43) | MMEMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL9963907 | 0.89 | MME (0.44) | MMEMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL9963880 | 0.89 | MME (0.44) | MMEMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL9963906 | 0.89 | MME (0.44) | MMEMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL20066495 | 0.82 | MME (0.38) | MMEMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL9966174 | 0.81 | MME (0.46) | MME | |
| SCHEMBL9966382 | 0.81 | MME (0.46) | MME | |
| SCHEMBL9979898 | 0.81 | MME (0.46) | MME | |
| SCHEMBL14234358 | 0.80 | MME (0.34) | MMEMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL15474172 | 0.80 | MME (0.46) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759813-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200031847-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759813-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885MAPK13 3549/4885MAPK12 2895/4885 |
| US-20200031847-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885MAPK13 3549/4885MAPK12 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.